European Journal of Neurology

Cover image for European Journal of Neurology

November 2001

Volume 8, Issue Supplement s5

Pages v–v, 1–202

  1. Foreword

    1. Top of page
    2. Foreword
    3. Section I: Scientific and clinical basis for use of botulinum toxin type A in the management of cerebral palsy
    4. Section II: Clinical considerations I: managing the ambulant patient
    5. Section III: Clinical considerations II: managing the marginally ambulant patient
    6. Section IV: Clinical considerations III: managing the patient with upper limb involvement
    7. Section V: Clinical considerations IV: evaluating treatment success
    1. Foreword (page v)

      H. K. Graham

      Version of Record online: 21 DEC 2001 | DOI: 10.1046/j.1468-1331.2001.00033.x

  2. Section I: Scientific and clinical basis for use of botulinum toxin type A in the management of cerebral palsy

    1. Top of page
    2. Foreword
    3. Section I: Scientific and clinical basis for use of botulinum toxin type A in the management of cerebral palsy
    4. Section II: Clinical considerations I: managing the ambulant patient
    5. Section III: Clinical considerations II: managing the marginally ambulant patient
    6. Section IV: Clinical considerations III: managing the patient with upper limb involvement
    7. Section V: Clinical considerations IV: evaluating treatment success
  3. Section II: Clinical considerations I: managing the ambulant patient

    1. Top of page
    2. Foreword
    3. Section I: Scientific and clinical basis for use of botulinum toxin type A in the management of cerebral palsy
    4. Section II: Clinical considerations I: managing the ambulant patient
    5. Section III: Clinical considerations II: managing the marginally ambulant patient
    6. Section IV: Clinical considerations III: managing the patient with upper limb involvement
    7. Section V: Clinical considerations IV: evaluating treatment success
    1. A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures (pages 75–87)

      K. Desloovere, G. Molenaers, I. Jonkers, J. De Cat, L. De Borre, J. Nijs, M. Eyssen, P. Pauwels and P. De Cock

      Version of Record online: 21 DEC 2001 | DOI: 10.1046/j.1468-1331.2001.00040.x

    2. Single event multilevel botulinum toxin type A treatment and surgery: similarities and differences (pages 88–97)

      G. Molenaers, K. Desloovere, J. De Cat, I. Jonkers, L. De Borre, P. Pauwels, J. Nijs, G. Fabry and P. De Cock

      Version of Record online: 21 DEC 2001 | DOI: 10.1046/j.1468-1331.2001.00041.x

  4. Section III: Clinical considerations II: managing the marginally ambulant patient

    1. Top of page
    2. Foreword
    3. Section I: Scientific and clinical basis for use of botulinum toxin type A in the management of cerebral palsy
    4. Section II: Clinical considerations I: managing the ambulant patient
    5. Section III: Clinical considerations II: managing the marginally ambulant patient
    6. Section IV: Clinical considerations III: managing the patient with upper limb involvement
    7. Section V: Clinical considerations IV: evaluating treatment success
    1. The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial (pages 109–119)

      R. N. Boyd, F. Dobson, J. Parrott, S. Love, J. Oates, A. Larson, G. Burchall, P. Chondros, J. Carlin, G. Nattrass and H. K. Graham

      Version of Record online: 21 DEC 2001 | DOI: 10.1046/j.1468-1331.2001.00043.x

    2. Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure (pages 120–126)

      M. Linder, G. Schindler, U. Michaelis, S. Stein, J. Kirschner, V. Mall, S. Berweck, R. Korinthenberg and F. Heinen

      Version of Record online: 21 DEC 2001 | DOI: 10.1046/j.1468-1331.2001.00044.x

    3. Spasticity management in the child with spastic quadriplegia (pages 127–135)

      M. E. Gormley Jr., L. E. Krach and L. Piccini

      Version of Record online: 21 DEC 2001 | DOI: 10.1046/j.1468-1331.2001.00045.x

  5. Section IV: Clinical considerations III: managing the patient with upper limb involvement

    1. Top of page
    2. Foreword
    3. Section I: Scientific and clinical basis for use of botulinum toxin type A in the management of cerebral palsy
    4. Section II: Clinical considerations I: managing the ambulant patient
    5. Section III: Clinical considerations II: managing the marginally ambulant patient
    6. Section IV: Clinical considerations III: managing the patient with upper limb involvement
    7. Section V: Clinical considerations IV: evaluating treatment success
  6. Section V: Clinical considerations IV: evaluating treatment success

    1. Top of page
    2. Foreword
    3. Section I: Scientific and clinical basis for use of botulinum toxin type A in the management of cerebral palsy
    4. Section II: Clinical considerations I: managing the ambulant patient
    5. Section III: Clinical considerations II: managing the marginally ambulant patient
    6. Section IV: Clinical considerations III: managing the patient with upper limb involvement
    7. Section V: Clinical considerations IV: evaluating treatment success

SEARCH

SEARCH BY CITATION